SCHEMBL2433203

SCHEMBL2433203

Ic1cnc2nc(-c3ccc(-c4cnco4)cc3)cn2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.42
NOTUM Q6P988 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
PTK2 Q05397 1/20 0.41
RAB9A P51151 5/20 0.40
KDM4E B2RXH2 5/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
APP P05067 2/20 0.40
KEAP1 Q14145 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
LTA4H P09960 1/20 0.37
ROCK2 O75116 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HPGD P15428 3/20 0.35
NPC1 O15118 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432450 0.84 RAB9A (0.59) GAANOTUMLMNAPKMPTK2
SCHEMBL2429956 0.80 APP (0.56) GAANOTUMLMNAPKMPTK2
SCHEMBL5776840 0.77 RAB9A (0.57) GAARAB9AKDM4EMAPTSMN1; SMN2
SCHEMBL1726397 0.77 RAB9A (0.46) GAARAB9AKDM4EMAPTSMN1; SMN2
SCHEMBL14076028 0.77 KDM4E (0.57) GAAPKMRAB9AKDM4EMAPT
SCHEMBL14076026 0.74 APP (0.71) RAB9AKDM4EMAPTSMN1; SMN2APP
SCHEMBL10187964 0.71 PKM (0.64) GAANOTUMLMNAPKMPTK2
SCHEMBL2428137 0.70 NPC1 (0.65) GAALMNAPKMRAB9AKDM4E
SCHEMBL12291859 0.70 NPC1 (0.65) GAALMNAPKMRAB9AKDM4E
SCHEMBL2428682 0.69 GAA (0.58) GAANOTUMLMNAPKMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP claimed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 GAA 452/4885NOTUM 4229/4885LMNA 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.